Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 July 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) approved two new drug entities for treating, respectively, certain forms of breast cancer and multiple myeloma on Friday, 20 July. The approvals capped off a busy week for the agency, marking the fourth approval and second new molecular entity in the five-day period.
Afinitor (everolimus), manufactured by Novartis Pharmaceuticals, was approved for the treatment of postmenopausal women with advanced formone-receptor positive, HER2-negative breast cancer. The drug was first approved in 2009 for the treatment of advanced renal cell carcinoma after failure of treatment with sunitinib or sorefenib.
FDA's 20 July approval of the drug for a new indication highlights the drug's status as a first-in-class drug for breast cancer. "This is the first approval from the class of drugs known as mTOR inhibitors for the treatment of postmenopausal women with advanced hormone-receptor positive breast cancer," said Richard Pazdur, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and Research (CDER).
Pazdur added that the drug's approval is "another example of the value of continuing to study drugs in additional types of cancer after their initial approval."
The agency's second approval was for Onyx Pharmaceuticals' Kyprolis (carfilzomib), indicated for the treatment of multiple myeloma. The new molecular entity is intended for use in patients with particularly aggressive forms of myeloma who have already received Velcade (bortezomib) and immunomodulatory therapy yet continue to see disease progression.
The drug received approval under FDA's accelerated approval regulations, and Onyx will be required to complete its clinical trial comparing the safety and efficacy of Kyprolis with lenalidomide dexamethasone by December 2013. Interim results of the trial formed the basis of approval, and complete results of the trial are due to FDA by June 2014.
Onyx will also be required to conduct six additional postmarketing studies for the drug to assess its potential for cardiac toxicities, pulmonary toxicities, and the general safety of Kyprolis when patients receive a standard, 30-minute intravenous infusion. A final trial will assess whether the drug is suitable for use in patients with "varying degrees of renal impairments and those on chronic dialysis," wrote FDA in its approval letter.
The approvals were FDA's third and fourth of the week, coming days after the agency approved Vivus Inc's Qsymia (phentermine and topiramate) for the treatment of obesity and Ferring Pharmaceuticals' Prepopik (sodium picosulfate, magnesium oxide and citric acid) for use in colonoscopy preparation.
Read more:
FDA approves Afinitor for advanced breast cancer
FDA approves Kyprolis for some patients with multiple myeloma
Tags: Ferring, Multiple Myeloma, Onyx, HER2, Breast Cancer, Pazdur, Latest News, approval, NME
Regulatory Focus newsletters
All the biggest regulatory news and happenings.